HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen
HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen
About this item
Full title
Author / Creator
Publisher
Athens: D.A. Spandidos
Journal title
Language
English
Formats
Publication information
Publisher
Athens: D.A. Spandidos
Subjects
More information
Scope and Contents
Contents
The human epidermal growth factor receptor (HER) 4 is a relative of HER2 and has been associated to endocrine breast cancer and prediction of tamoxifen response. In addition to PI3K/Akt and MAPK pathway activation, ligand binding to HER4 triggers proteolytic cleavage and release of an intracellular receptor domain (4ICD) with signaling properties....
Alternative Titles
Full title
HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_511603
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_511603
Other Identifiers
ISSN
1019-6439,1791-2423
E-ISSN
1791-2423
DOI
10.3892/ijo.2015.3108
